Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12224.165 | 0.7369 | 0.4606 | 0.9714 | |
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12224.165 | 0.0144 | -0.9746 | 0.9714 | |
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12224.165 | 0.0112 | -0.9804 | 0.9714 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11854.158 | 0.9566 | 0.9366 | 1.3776 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11854.158 | 1.0238 | 1.0345 | 1.3776 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11854.158 | 0.9261 | 0.8915 | 1.3776 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11854.158 | 0.9558 | 0.9354 | 1.3776 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11854.158 | 0.7646 | 0.6459 | 1.3776 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11854.158 | 0.8612 | 0.7943 | 1.3776 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11854.158 | 0.7274 | 0.5874 | 1.3776 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11854.158 | 0.1089 | -0.6001 | 1.3776 | |
| BT-20 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11854.158 | 0.0127 | -0.9160 | 1.3776 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12056.158 | 0.9029 | 0.8044 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12056.158 | 0.9383 | 0.8757 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12056.158 | 0.8143 | 0.6262 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12056.158 | 0.4999 | -0.0051 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12056.158 | 0.2184 | -0.5678 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12056.158 | 0.2178 | -0.5692 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12056.158 | 0.1782 | -0.6479 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12056.158 | 0.0431 | -0.9156 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12056.158 | 0.0088 | -0.9829 | 0.9929 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12178.158 | 0.9923 | 0.9790 | 0.7379 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12178.158 | 0.9717 | 0.9238 | 0.7379 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12178.158 | 0.9046 | 0.7458 | 0.7379 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12178.158 | 0.6467 | 0.1079 | 0.7379 |